Clinical Trial

Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC

Study acronym: RICE
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of adebrelimab with or without induction chemotherapy followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-14.
Trial Details
NCT Number NCT06510660
Lead Sponsor Fujian Medical University Union Hospital
Collaborators: Sun Yat-Sen University Cancer Center
Conditions Esophageal Squamous Cell Carcinoma, Immunotherapy, Biomarkers
Enrollment 48 participants
Start Date 2024-04-11
Primary Completion 2025-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2024-09-19